PureTech Health Osake

PureTech Health EBITDA

Delisted·19.6.2026

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä PureTech Health (PRTC.L) 4.8.2026 päivämäärällä on −136,10 M USD. Edellisenä vuonna EBITDA (Tulos ennen korkoja, veroja ja poistoja) oli −146,20 M USD — muutos −6,91 % (korkeampi).

EBITDA

−136,10 MUSD

YoY

−6,91%

Viimeksi päivitetty:

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä PureTech Health on 2026 −136,10 M USD. EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä PureTech Health oli 2025 −146,20 M USD. Se laskee −6,91% korkeampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

PureTech Health Osakeanalyysi

Mitä PureTech Health tekee? PureTech Health is an innovative company specializing in the development of novel medical therapies and solutions. The company was founded in 2002 by Daphne Zohar and is headquartered in Boston, USA. PureTech Health is listed on the London Stock Exchange and has become one of the leading biotech companies in recent years. The company's business model is based on identifying medical needs and developing new products and therapies to meet those needs. It utilizes cutting-edge technologies to work quickly and effectively. Research and development are closely linked in an iterative process. PureTech Health's main focus is oncology, specifically developing immune-oncology therapies that target the patient's immune system to strengthen their body's defense against cancer cells. The company has also developed an innovative drug discovery system that combines nanotechnology and artificial intelligence. Another focus area for PureTech Health is gastroenterology. The company has developed a novel technology that selectively releases medical substances in the intestine, allowing targeted treatment of gastrointestinal diseases. PureTech Health has also developed a new method for diagnosing colorectal cancer based on the identification of bacteria in feces. In the field of neuropsychiatric disorders, the company has promising research results. It has developed a new technology that enables targeted manipulation of the central nervous system, allowing for the treatment of conditions such as depression, anxiety disorders, and ADHD. To this end, PureTech Health has developed a novel nasal spray that delivers the active ingredients directly to the brain. Biosensing is another area of focus for PureTech Health. The company has developed a novel technology that allows for the measurement of medical parameters such as blood sugar, cholesterol, and blood pressure. The sensors are available in the form of patches or other wearable devices and are easy and convenient to use. This technology is intended to help older people and those with chronic illnesses better monitor their health. Overall, PureTech Health is an innovative biotech company that is constantly seeking novel medical solutions. It operates in various areas and has promising products and therapies in the pipeline. With its close integration of research and development, PureTech Health is able to quickly and flexibly respond to market changes. With strong management and an experienced team, the company is well-positioned for further growth in the coming years. PureTech Health on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset PureTech Health osakkeesta

Yhtiön PureTech Health EBITDA (Tulos ennen korkoja, veroja ja poistoja) on −136,10 M USD vuonna 2026.

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä PureTech Health muuttui arvosta −146,20 M USD arvoon −136,10 M USD, mikä edustaa −6,91 % muutosta. Arvo on korkeampi kuin edellisenä vuonna.

Eurpoolissa voit löytää EBITDA (Tulos ennen korkoja, veroja ja poistoja) PureTech Health:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

EBITDA mittaa operatiivista suorituskykyä ennen rahoitusrakenteen, veroympäristön ja muiden kuin käteispoisto-osuuksien vaikutusta.

EBITDA = EBIT + Poistot

EBITDA (Tulos ennen korkoja, veroja ja poistoja):n USD on sijoittajille tärkeä tekijä. Muutokset tässä tunnusluvussa voivat signaloida parantuvia tai heikentyneitä perustekijöitä, mikä vaikuttaa suoraan osakekurssiin. Eulerpoolissa voit seurata EBITDA (Tulos ennen korkoja, veroja ja poistoja):n PureTech Health historiallisesti ja reaaliajassa.

Access this data via the Eulerpool API

Tuloslaskelma — PureTech Health

Kaikki tunnusluvut — PureTech Health